Innovative Bispecific Nanobody Targeting CD3 Complex and TNFRSF17 for Multiple Myeloma Immunotherapy
VHH-P434 is a humanized nanobody-based bispecific antibody designed to target the CD3 Complex (T Cell Receptor Complex) and TNF receptor superfamily member 17 (TNFRSF17). Currently undergoing biological testing, this molecule holds promise for the treatment of multiple myeloma. By engaging both T-cells and malignant plasma cells, VHH-P434 aims to provide a novel immunotherapeutic avenue for patients with this challenging hematological malignancy. Its dual-targeting approach leverages advances in nanobody engineering and bispecific antibody modalities to potentially address key unmet needs in multiple myeloma therapy.
| Candidate | VHH-P434 |
| Target | CD3 Complex (T Cell Receptor Complex) TNF receptor superfamily member 17 (TNFRSF17) |
| Modality | humanized bispecific VHH |
| Indication | Multiple Myeloma |
Licensing Opportunity
VHH-P434 is available for strategic partnerships and licensing opportunities. Partners interested in advancing innovative therapies for multiple myeloma are welcome to collaborate on the further development and commercialization of this promising bispecific nanobody program.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P434 |
Modality
VHH-P434 is a bispecific antibody constructed from a single-domain antibody against TNFRSF17 fused to an anti-CD3 antibody via a flexible (G4S)3 linker, and it is expressed in HEK293T cells. The use of nanobody technology imparts several structural advantages, including reduced molecular size and enhanced tissue penetration, which are particularly beneficial in targeting the dense microenvironment of multiple myeloma. The structural stability and solubility of single-domain antibodies further support robust expression and manufacturability. These properties position VHH-P434 as a next-generation modality capable of enhancing immune synapse formation and tumor infiltration, offering potential improvements over conventional antibody-based therapies.
Target
CD3 Complex and TNFRSF17 are two highly relevant therapeutic targets in multiple myeloma. The CD3 Complex is a critical component of the T cell receptor, involved in signal transduction for T cell activation, and is predominantly expressed on the surface of T lymphocytes. TNFRSF17, also known as BCMA, is a member of the tumor necrosis factor receptor superfamily and is highly expressed on malignant plasma cells, including those in multiple myeloma. Both CD3 Complex and TNFRSF17 are attractive targets for immunotherapy due to their distinct expression profiles and biological roles. Targeting CD3 Complex enables T-cell redirection, while engagement of TNFRSF17 ensures selective recognition of tumor cells. VHH-P434 strategically targets both CD3 Complex and TNFRSF17, aiming to maximize cytotoxic immune responses against myeloma cells and exemplifying a forward-looking approach in bispecific immunotherapeutic design.
Mechanism of Action
VHH-P434 acts as a bispecific T-cell engager by simultaneously binding to TNFRSF17 on multiple myeloma cells and the CD3 Complex on T lymphocytes. This dual engagement brings T cells into close proximity with malignant plasma cells, triggering T-cell activation and a targeted cytotoxic response. By modulating signal transduction pathways, VHH-P434 augments the immune-mediated elimination of TNFRSF17-expressing cells. The nanobody-based architecture facilitates robust immune synapse formation and can be further developed into formats such as antibody-drug conjugates or alternative bispecific constructs, broadening its therapeutic applicability. Through precise redirection of immune effector cells, VHH-P434 offers a targeted immunotherapeutic strategy for multiple myeloma.
Multiple Myeloma
Multiple myeloma is a malignant hematologic disorder characterized by the clonal proliferation of plasma cells in the bone marrow. It accounts for a significant proportion of blood cancers, with rising incidence in aging populations worldwide. Standard treatment approaches include chemotherapy, immunomodulatory agents, proteasome inhibitors, and autologous stem cell transplantation. More recently, antibody-based and cellular immunotherapies have expanded the therapeutic landscape. Despite these advances, multiple myeloma remains incurable for most patients, with many experiencing relapse or resistance to existing therapies. Key challenges include tumor heterogeneity, immunosuppressive microenvironment, and toxicity associated with current treatments. There is an urgent need for novel immuno-oncology strategies that deliver improved specificity and efficacy. VHH-P434 addresses these gaps by engaging both T cells and tumor cells via distinct targets, potentially overcoming immune evasion and enhancing tumor cell clearance in multiple myeloma.